Keeps Biopharma Inc. (KOSDAQ:256940)
South Korea flag South Korea · Delayed Price · Currency is KRW
18,390
-330 (-1.76%)
At close: Jun 27, 2025, 3:30 PM KST

Keeps Biopharma Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Operating Revenue
136,521127,58392,13314,6174,26115,217
Upgrade
Other Revenue
--0--0-
Upgrade
136,521127,58392,13314,6174,26115,217
Upgrade
Revenue Growth (YoY)
20.46%38.48%530.30%243.09%-72.00%7.23%
Upgrade
Cost of Revenue
116,317110,34379,33613,5745,05011,269
Upgrade
Gross Profit
20,20517,24012,7981,044-788.973,947
Upgrade
Selling, General & Admin
14,6739,9217,3026,0765,4753,032
Upgrade
Research & Development
1,246801.381,4502,1642,810829.9
Upgrade
Other Operating Expenses
400.13226.14441.1641.3746.2568.48
Upgrade
Operating Expenses
17,32211,0159,7389,95811,5184,334
Upgrade
Operating Income
2,8826,2253,060-8,915-12,307-386.94
Upgrade
Interest Expense
-4,543-3,731-2,030-934.7-1,690-1,665
Upgrade
Interest & Investment Income
868.91733.241,0121,075431.37303.49
Upgrade
Earnings From Equity Investments
-1,509-1,6094,930-3,998-3,081-2,184
Upgrade
Currency Exchange Gain (Loss)
1,6612,307531.91,4801,869-1,135
Upgrade
Other Non Operating Income (Expenses)
-1,333-1,429-3,132-3,23710.543.76
Upgrade
EBT Excluding Unusual Items
-1,9732,4964,372-14,530-14,767-5,064
Upgrade
Impairment of Goodwill
-81.54-81.54----
Upgrade
Gain (Loss) on Sale of Investments
853.02847.491,033-203.11-2,5192,871
Upgrade
Gain (Loss) on Sale of Assets
46.9124.15-33.362.44-19.15-82.9
Upgrade
Other Unusual Items
84.5883.7-853.14--
Upgrade
Pretax Income
-1,0703,3705,372-13,877-17,305-2,276
Upgrade
Income Tax Expense
1,7591,7581,909-1,837-1,074271.45
Upgrade
Earnings From Continuing Operations
-2,8291,6123,463-12,040-16,231-2,547
Upgrade
Minority Interest in Earnings
-4,459-498.28467.19665.13913.17140.9
Upgrade
Net Income
-7,2881,1133,930-11,375-15,317-2,406
Upgrade
Net Income to Common
-7,2881,1133,930-11,375-15,317-2,406
Upgrade
Net Income Growth
--71.67%----
Upgrade
Shares Outstanding (Basic)
191919191715
Upgrade
Shares Outstanding (Diluted)
191919191715
Upgrade
Shares Change (YoY)
-0.19%0.38%0.40%8.22%18.22%14.07%
Upgrade
EPS (Basic)
-388.1459.39209.62-607.03-884.60-164.28
Upgrade
EPS (Diluted)
-388.5459.00209.00-607.03-884.60-164.28
Upgrade
EPS Growth
--71.77%----
Upgrade
Free Cash Flow
-10,177-1,787-1,048-962.12-8,471-2,780
Upgrade
Free Cash Flow Per Share
-542.00-94.64-55.71-51.34-489.19-189.82
Upgrade
Gross Margin
14.80%13.51%13.89%7.14%-18.52%25.94%
Upgrade
Operating Margin
2.11%4.88%3.32%-60.99%-288.86%-2.54%
Upgrade
Profit Margin
-5.34%0.87%4.27%-77.82%-359.52%-15.81%
Upgrade
Free Cash Flow Margin
-7.46%-1.40%-1.14%-6.58%-198.82%-18.27%
Upgrade
EBITDA
5,5928,8074,502-7,921-11,495217.34
Upgrade
EBITDA Margin
4.10%6.90%4.89%-54.19%-269.79%1.43%
Upgrade
D&A For EBITDA
2,7102,5821,442993.33812.4604.28
Upgrade
EBIT
2,8826,2253,060-8,915-12,307-386.94
Upgrade
EBIT Margin
2.11%4.88%3.32%-60.99%-288.86%-2.54%
Upgrade
Effective Tax Rate
-52.17%35.53%---
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.